Tasly Pharmaceutical Group Co., Ltd (600535.SS)
CNY 14.7
(0.75%)
CNY 14.7
(0.75%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 2.6 Billion | 2.28 Billion | 2.8 Billion | 1.79 Billion | 1.68 Billion | 1.49 Billion |
| Net Income | 1.07 Billion | -340.76 Million | 2.4 Billion | 1.08 Billion | 1 Billion | 1.59 Billion |
| Depreciation & Amortization | 516.13 Million | 516.86 Million | 487.76 Million | 539.67 Million | 386.72 Million | 356.96 Million |
| Deferred income taxes | 15.52 Million | -45.92 Million | 1.66 Million | 47.33 Million | 6.6 Million | -15.49 Million |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 694.35 Million | 521.93 Million | 1.27 Billion | 30.48 Million | -416.26 Million | -998.98 Million |
| Other non-cash items | 715.38 Million | 1.58 Billion | -1.37 Billion | 131.14 Million | 706.52 Million | 543.88 Million |
| Investing Cash Flow | -2.66 Billion | -1.26 Billion | -42.83 Million | 865.85 Million | -492.98 Million | -641.83 Million |
| Investments in PPE | -668.81 Million | -403.44 Million | -571.72 Million | -408.81 Million | -730.77 Million | -780.1 Million |
| Acquisitions | -519.36 Million | -9.29 Million | 276.87 Million | 734 Million | -481.36 Thousand | -37.09 Million |
| Investment purchases | -1.78 Billion | -3.87 Billion | -1.5 Billion | -4.59 Billion | -6.03 Billion | -701.66 Million |
| Sales/Maturities of investments | 1.64 Billion | 3.01 Billion | 1.69 Billion | 4.72 Billion | 6.26 Billion | 795.88 Million |
| Other Investing Activities | -1.33 Billion | 5.67 Million | 68.83 Million | 411.43 Million | 9.92 Million | 81.15 Million |
| Financing Cash Flow | -675.79 Million | -236.13 Million | -2.48 Billion | -2.31 Billion | -2.38 Billion | 827.93 Million |
| Debt repayment | -650.65 Million | -2.23 Billion | -2.64 Billion | -6.3 Billion | -5.81 Billion | -9.79 Billion |
| Dividends payments | -493 Million | -493 Million | -495.71 Million | -497.61 Million | -452.37 Million | -860.24 Million |
| Common Stock Repurchased | - | -60.79 Million | -56.42 Million | -94.76 Million | -12.87 Million | -87.21 Million |
| Common Stock Issuance | - | 60.79 Million | 56.42 Million | 94.76 Million | 12.87 Million | - |
| Other Financing Activities | -751.49 Million | 2.54 Billion | 767.38 Million | 4.79 Billion | 4.33 Billion | 11.48 Billion |
| Accounts receivables | 1.24 Billion | 524.13 Million | 1.23 Billion | -397.93 Million | -22.82 Million | -744.91 Million |
| Accounts payables | -395.35 Million | 38.22 Million | 243.77 Million | 324.5 Million | -246.19 Million | -277.03 Million |
| Inventory | -220.72 Million | 5.49 Million | -198.36 Million | 56.57 Million | -153.84 Million | 38.45 Million |
| Other working capital | 67.75 Million | -45.92 Million | 1.66 Million | 47.33 Million | 6.6 Million | -1.03 Billion |
| Cash at beginning of period | 3.11 Billion | 2.1 Billion | 1.82 Billion | 1.49 Billion | 2.69 Billion | 1 Billion |
| Cash at end of period | 4.45 Billion | 2.91 Billion | 2.1 Billion | 1.82 Billion | 1.49 Billion | 2.69 Billion |
| Capital Expenditure | -668.81 Million | -403.44 Million | -571.72 Million | -408.81 Million | -730.77 Million | -780.1 Million |
| Effect of forex changes on cash | -1.26 Million | 30.1 Million | 1.93 Million | -12.14 Million | 3.84 Million | 1.32 Million |
| Net cash flow / Change in cash | 1.33 Billion | 813.87 Million | 276.97 Million | 334.16 Million | -1.19 Billion | 1.68 Billion |
| Free Cash Flow | 1.93 Billion | 1.88 Billion | 2.22 Billion | 1.38 Billion | 949.37 Million | 713.68 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 179.89 Million | 367.09 Million | 295.21 Million | 1.07 Billion | 38.64 Million | 325.32 Million |
| Depreciation & Amortization | - | 126.94 Million | 126.94 Million | 516.13 Million | 128.62 Million | -248.41 Million |
| Deferred income taxes | - | - | - | 15.52 Million | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | -28 Million | - | 694.35 Million | 1.08 Billion | -16.66 Million |
| Other non-cash items | 148.54 Million | 988.21 Million | -626.9 Million | 715.38 Million | 228.85 Million | 188.02 Million |
| Investing Cash Flow | -277.61 Million | -955.81 Million | -300.84 Million | -2.66 Billion | -2.33 Billion | 99.48 Million |
| Investments in PPE | -176.1 Million | -94.8 Million | -96.37 Million | -668.81 Million | -275.37 Million | -105.21 Million |
| Acquisitions | 421.57 Thousand | 9.33 Million | - | -519.36 Million | -488.96 Million | 381.85 Million |
| Investment purchases | -3.35 Billion | -2.45 Billion | -256.7 Million | -1.78 Billion | -260.99 Million | -8.78 Million |
| Sales/Maturities of investments | 3.34 Billion | 1.58 Billion | 52.61 Million | 1.64 Billion | 32.86 Million | 212.98 Million |
| Other Investing Activities | -94.89 Million | -2.02 Million | -371.2 Thousand | -1.33 Billion | -1.33 Billion | -381.34 Million |
| Financing Cash Flow | -1 Billion | -552.79 Million | 687.05 Million | -675.79 Million | -517.83 Million | 50.88 Million |
| Debt repayment | -446.24 Million | -340.79 Million | -41.93 Million | -650.65 Million | -564.62 Million | -61.42 Million |
| Dividends payments | - | -504.04 Million | -12.84 Million | -493 Million | -493 Million | -493 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -554.69 Million | -1.44 Billion | 728.99 Million | -751.49 Million | 525.67 Million | 128.03 Million |
| Accounts receivables | - | 58.8 Million | - | 1.24 Billion | 1.24 Billion | -165.81 Million |
| Accounts payables | - | - | - | -395.35 Million | - | -13.8 Million |
| Inventory | - | -86.81 Million | - | -220.72 Million | -220.72 Million | 149.15 Million |
| Other working capital | - | - | - | 67.75 Million | 67.75 Million | 13.8 Million |
| Cash at beginning of period | 4.45 Billion | 4.36 Billion | 4.45 Billion | 3.11 Billion | 4.31 Billion | 3.16 Billion |
| Cash at end of period | 3.63 Billion | 4.45 Billion | 4.36 Billion | 4.45 Billion | 4.45 Billion | 3.55 Billion |
| Capital Expenditure | -176.1 Million | -94.8 Million | -96.37 Million | -668.81 Million | -275.37 Million | -105.21 Million |
| Effect of forex changes on cash | - | 472.88 Thousand | 143.06 Thousand | -1.26 Million | -1.35 Million | -607.52 Thousand |
| Net cash flow / Change in cash | -823.9 Million | 99.3 Million | -90.34 Million | 1.33 Billion | 131.1 Million | 398.04 Million |
| Free Cash Flow | 152.33 Million | 1.13 Billion | -428.07 Million | 1.93 Billion | 1.21 Billion | 143.05 Million |
SHEL
603158
600398
0OJJ
ATUS
001525